What Investors Overlooked Before SRF Slid

If you only glanced at SRF’s latest quarter, with higher revenue and a wider net margin, the business might look comfortably on track. For SRF shareholders, the loss over the past year was 21.9%, including dividends. That gap between healthier reported results and a falling investment is hard to ignore. If you were weighing a purchase in October 2025, what could you reasonably have seen that hinted this mismatch might emerge?

SRF has already moved. See which of 191 high quality undervalued stocks still trade below our estimates.

The Two SRF Stories Investors Had To Weigh

SRF shares cost ₹3,192 at the start of the period, and investors were effectively choosing between two very different stories for the same business.

The bullish view pointed to a Fair Value of ₹3,650, a price implied by optimistic assumptions about the future. Supporters leaned on R&D driven launches in agrochemical and pharma intermediates during a global supply shortage, expecting strong demand and wider margins.

The bearish camp worked off a Fair Value of ₹2,080, reflecting a more cautious set of expectations. This side focused on the risk that tighter environmental rules and a faster shift to green materials would raise compliance costs and pressure earnings.

What The SRF Results Put To The Test

The clearest datapoint came from SRF’s Q1 2027 report. Revenue of ₹50,332.6m and net income of ₹7,588.7m, versus ₹38,186.2m and ₹4,323.2m a year earlier, arrived with net margin at 15.1% rather than 11.3%. That combination of higher sales, profit, and profitability leaned toward the optimistic margin thesis, while still not disproving regulatory and capital intensity worries.

The useful takeaway is simple. When a story hangs on margin expansion, do not just track the top line. Compare net margin percentages quarter by quarter to see whether the promised profitability shift is actually showing up.

What SRF’s Current Price Asks You To Believe

SRF now trades at ₹2,466 after a 21.9% loss over the past year, while the selected Narrative’s Fair Value sits above the current price based on its own assessment. The argument leans on specific fluorochemicals, pharma and films projects rather than a broad chemicals growth pitch.

For that higher Fair Value to hold, a buyer today would need to assume SRF executes its large capex program on time and within budget so new capacities deliver the earnings mix shift the Narrative describes.

"The view on SRF has shifted from a broad, sustainability and capacity led chemicals story to a more focused, long term build out of an integrated fluorochemicals, pharma and higher value films portfolio, anchored by specific capex projects and timelines."

One Narrative has put a figure on that disagreement. → See the Narrative with its higher Fair Value, assumptions and all

How Could You Get There Earlier?

Passing on this one could have spared you a loss. Where might you find the opposite surprise? Start looking for companies whose prices leave room for a better outcome than investors expect. These three trade below our estimated value.

• Company 1 - 44% below our estimate - expands higher margin omnichannel sales through new flagship stores and digital tools.
• Company 2 - 48% below our estimate - wins larger data center and smart building contracts as clients modernize infrastructure.
• Company 3 - 31% below our estimate - scales multichannel electronics retail as new digital tools improve cross channel efficiency.

That is three of the list. See all 203 companies with the balance sheet to back it up →

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com